Detailed Information on Publication Record
2021
Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study
SLÁVIK, Marek, Petr BURKOŇ, Iveta SELINGEROVÁ, Pavel KRUPA, Tomáš KAZDA et. al.Basic information
Original name
Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study
Authors
SLÁVIK, Marek (703 Slovakia, belonging to the institution), Petr BURKOŇ (203 Czech Republic, guarantor, belonging to the institution), Iveta SELINGEROVÁ (203 Czech Republic, belonging to the institution), Pavel KRUPA (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Jaroslava STANKOVA (203 Czech Republic), Tomas NIKL (203 Czech Republic), Renata HEJNOVÁ (203 Czech Republic, belonging to the institution), Zdeněk ŘEHÁK (203 Czech Republic), Pavel OŠMERA (203 Czech Republic), Tomáš PROCHÁZKA (203 Czech Republic, belonging to the institution), Eva DVORAKOVA (203 Czech Republic), Petr POSPÍŠIL (203 Czech Republic, belonging to the institution), Peter GRELL (703 Slovakia, belonging to the institution), Pavel ŠLAMPA (203 Czech Republic, belonging to the institution) and Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution)
Edition
Medicina-Lithuania, Basel, MDPI, 2021, 1010-660X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.948
RIV identification code
RIV/00216224:14110/21:00120228
Organization unit
Faculty of Medicine
UT WoS
000735791500001
Keywords in English
gastroesophageal junction cancer; PET; CT; radiotherapy; neoadjuvant chemoradiotherapy
Tags
International impact, Reviewed
Změněno: 16/5/2022 09:12, Mgr. Tereza Miškechová
Abstract
V originále
Background and Objectives: The treatment of gastroesophageal junction (GEJ) adenocarcinoma consists of either perioperative chemotherapy or preoperative chemoradiotherapy. Radiotherapy (RT) in the neoadjuvant setting is associated with a higher probability of resections with negative margins (R0) and better tumor regression rate, which might be enhanced by incrementing RT dose with potential impact on treatment results. This virtual planning study demonstrates the feasibility of increasing the dose to GEJ tumor and involved nodes using PET/CT imaging. Materials and Methods: 16 patients from the chemoradiotherapy arm of the phase II GastroPET study were treated by a prescribed dose of 45.0 Gray (Gy) in 25 fractions. PET/CT was performed before treatment. The prescribed dose was virtually boosted on PET/CT-positive areas to 54.0 Gy by 9 Gy in 5 fractions. Dose-volume histograms (DVH) were compared, and normal tissue complication (NTCP) modeling was performed for both dose schedules. Results: DVHs were exceeded in mean heart dose in one case for 45.0 Gy and two cases for 54.0 Gy, peritoneal space volume criterion V-45Gy < 195 ccm in three cases for 54.0 Gy and V-15Gy < 825 ccm in one case for both dose schedules. The left lung volume of 25 Gy isodose exceeded 10% in most cases for both schedules. The NTCP values for the heart, spine, liver, kidneys and intestines were zero for both schemes. An increase in NTCP value was for lungs (median 3.15% vs. 4.05% for 25 x 1.8 Gy and 25 + 5 x 1.8 Gy, respectively, p = 0.013) and peritoneal space (median values for 25 x 1.8 Gy and 25 + 5 x 1.8 Gy were 3.3% and 14.25%, respectively, p < 0.001). Conclusion: Boosting PET/CT-positive areas in RT of GEJ tumors is feasible, but prospective trials are needed.
Links
LM2018128, research and development project |
| ||
NV17-29389A, research and development project |
| ||
90125, large research infrastructures |
|